SANTA ROSA, Calif., July 2, 2026
Endologix LLC announced the publication of 36-month results from its DETOUR2 clinical trial in the Journal of the Society for Cardiovascular Angiography and Interventions (JSCAI), demonstrating that Percutaneous Transmural Arterial Bypass (PTAB) using the DETOUR™ System delivered durable vessel patency, sustained symptom relief, and high limb preservation in patients with complex superficial femoral artery (SFA) disease. The prospective, international, multicenter study enrolled 202 patients across 32 clinical sites, evaluating individuals with long-segment femoropopliteal (FP) lesions exceeding 30 cm, one of the most difficult forms of peripheral arterial disease (PAD) to treat. The published findings support the DETOUR System as a minimally invasive alternative to open surgical bypass, providing durable clinical outcomes through three years while reinforcing its role in managing complex vascular disease.
Three-Year Clinical Results Show Durable Performance
The DETOUR2 trial evaluated patients with an average lesion length of 32.7 cm, including 96% chronic total occlusions (CTOs) and 70% severely calcified lesions, representing a highly challenging patient population. At 36 months, the study reported 58.2% primary patency, while 84.0% of treated vessels remained free from complete occlusion. The freedom from clinically driven target lesion revascularization (CD-TLR) reached 66.8%, indicating that relatively few patients required repeat interventions. Additionally, 64.5% remained free from major adverse limb events (MALE), while the major amputation-free rate remained exceptionally high at 97.9%, unchanged from the 12-month analysis. Importantly, the incidence of symptomatic deep vein thrombosis (DVT) remained low at 4.1%, with no pulmonary embolism cases reported, further supporting the long-term safety profile of the DETOUR System.
Minimally Invasive PTAB Improves Symptoms and Limb Preservation
The study demonstrated that 96.7% of patients achieved clinical success, defined by an improvement in Rutherford clinical classification, confirming sustained symptom relief and improved functional outcomes over three years. Lead investigator Dr. Prakash Krishnan noted that long-segment femoropopliteal disease remains one of the greatest challenges in peripheral vascular intervention, and the DETOUR2 data highlight the ability of percutaneous bypass to achieve durable outcomes with favorable safety. John Liddicoat, President and CEO of Endologix, emphasized that the technology enables physicians to achieve long-term durability comparable to surgical bypass while avoiding the invasiveness associated with open procedures, representing an important advancement for patients with complex PAD.
Advertisement
DETOUR System Expands Treatment Options for Complex PAD
The DETOUR™ System utilizes an innovative Percutaneous Transmural Arterial Bypass (PTAB) technique that restores blood flow by routing stents through the femoral vein via a controlled transmural passage to bypass diseased segments of the superficial femoral artery. The technology is particularly suited for patients with 20–46 cm lesions, individuals who have experienced failed prior endovascular procedures, or those considered poor candidates for open surgical bypass. Building on the positive DETOUR2 findings, Endologix also reported continued progress with the PTAB1 real-world registry, which has now enrolled more than 200 patients to further evaluate long-term safety and clinical performance. Together, these studies strengthen the growing clinical evidence supporting the DETOUR System as a promising minimally invasive treatment option for complex peripheral arterial disease.
Source: Endologix, press release
